Diagnosis and management of resistant hypertension
Sep 24, 2024
auto_awesome
Dr. Miguel Camafort, a specialist in resistant hypertension from Barcelona, shares his expertise on tackling this challenging condition. He emphasizes the differences in diagnosis and management standards between American and European practices. The conversation dives into the importance of patient adherence and lifestyle changes as essential components of effective treatment. Dr. Camafort also discusses innovative therapies, including renal denervation, and highlights new drug developments that could shape future management strategies.
Accurately diagnosing resistant hypertension involves differentiating true cases from pseudoresistance through thorough assessment and out-of-office blood pressure measurements.
Emerging therapies like endothelin receptor agonists and renal denervation therapy illustrate innovative approaches being explored for managing resistant hypertension effectively.
Deep dives
Understanding Resistant Hypertension
Resistant hypertension is defined as hypertension that persists despite treatment with three different antihypertensive medications. Guidelines differ internationally, with European criteria requiring a blood pressure over 140/90 mmHg, while American guidelines set the threshold at 130/80 mmHg. Notably, the inclusion of patients requiring four medications for control can suggest resistant hypertension in the American guidelines, expanding the definition's scope. Accurately identifying this condition is crucial, as it correlates significantly with increased risks of hypertension-mediated organ damage and cardiovascular events.
Identifying and Managing Resistant Hypertension
The diagnosis of resistant hypertension involves careful assessment, including out-of-office blood pressure measurements to distinguish true resistant hypertension from pseudoresistance due to factors like poor medication adherence. Additional tests are necessary to rule out secondary hypertension causes, such as renal artery stenosis or primary hyperaldosteronism, which can complicate treatment. Managing these patients starts with lifestyle modifications, emphasizing the education of dietary changes and physical activity tailored to individual capabilities. Following these adjustments, maximizing the dosage of diuretics and considering additional medications, like spironolactone, is essential for effective management.
Future Treatments and Clinical Considerations
Emerging therapies are being explored to aid patients with resistant hypertension, including new drugs such as endothelin receptor agonists and aldosterone synthase inhibitors, which show promise in clinical trials. Furthermore, renal denervation therapy is under investigation, though its long-term effectiveness remains uncertain, warranting further studies before it can be standardized in treatment protocols. Guidelines suggest that renal denervation may be considered in cases where conventional management fails, highlighting the need for more definitive research. Collectively, these advancements offer hope for better management strategies for patients suffering from resistant hypertension.
In this episode of the Heart podcast, Digital Media Editor, Professor James Rudd, is joined by Dr Miguel Camafort from Barcelona. They discuss his approach to the diagnosis and management of resistant hypertension. If you enjoy the show, please leave us a podcast review at https://itunes.apple.com/gb/podcast/heart-podcast/id445358212?mt=2 or wherever you get your podcasts - it's really helpful.